Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.64 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29964637 | 1.00 | CHRNB2 (0.64) | CHRNB2CHRNA4POLBMAPTALDH1A1 | |
| SCHEMBL16427580 | 0.85 | CHRNB2 (0.51) | CHRNB2CHRNA4POLB | |
| SCHEMBL29067311 | 0.82 | CHRNB2 (0.77) | CHRNB2CHRNA4POLBMAPTALDH1A1 | |
| SCHEMBL27067392 | 0.81 | CHRNB2 (0.74) | CHRNB2CHRNA4POLBMAPTALDH1A1 | |
| SCHEMBL23089610 | 0.79 | CHRNB2 (0.46) | CHRNB2CHRNA4POLBMAPTALDH1A1 | |
| SCHEMBL29814695 | 0.79 | CHRNB2 (0.46) | CHRNB2CHRNA4POLBMAPTALDH1A1 | |
| SCHEMBL16427595 | 0.79 | CNR2 (0.47) | POLBMAPTALDH1A1HTTKDM4E | |
| SCHEMBL29695798 | 0.78 | CHRNB2 (0.55) | CHRNB2CHRNA4POLBMAPTALDH1A1 | |
| SCHEMBL594369 | 0.78 | CHRNB2 (1.00) | CHRNB2CHRNA4 | |
| SCHEMBL18256503 | 0.78 | POLB (0.55) | POLBMAPTALDH1A1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| EP-4712969-A1 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4676927-A1 | HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025007863-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-09 | — | — | WO | disclosed |
| US-20240425479-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-12-26 | — | — | US | disclosed |
| US-20240408169-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2024187049-A1 | HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| EP-3735411-B1 | 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE | AC IMMUNE SA (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-4330246-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | Ontario Institute for Cancer Research (OICR) (CA) | 2024-03-06 | — | — | EP | disclosed |
| EP-2007728-A1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-12-31 | — | — | EP | disclosed |
| WO-2008099000-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008099000-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-21 | — | — | WO | disclosed |
| WO-2007116922-A1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007116922-A1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | WO | disclosed |
| CN-1950371-A | Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands | PFIZER LTD (US) | 2007-04-18 | — | — | CN | disclosed |
| EP-1756104-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | Pfizer Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005111036-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | PFIZER LIMITED (GB) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | LUNN GRAHAM | 2005-11-17 | — | — | US | disclosed |
| EP-1595881-A1 | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands | Pfizer Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | HRH4, HRH3, HRH1 | CHRNB2 139/4885CHRNA4 24/4885POLB 3163/4885 |
| US-20240408169-A1 | CYCLIN INHIBITORS | CCNI, CDK2, CDK1 | CHRNB2 4847/4885CHRNA4 4872/4885POLB 110/4885 |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | TYK2, ERBB2, ROS1 | CHRNB2 2163/4885CHRNA4 3633/4885POLB 2978/4885 |
| US-20240425479-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | DCK, CMPK1, WNK1 | CHRNB2 4387/4885CHRNA4 4593/4885POLB 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.